{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:10:04Z","timestamp":1738656604002,"version":"3.35.0"},"reference-count":58,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seralutinib, an inhaled, small\u2010molecule tyrosine kinase inhibitor in clinical development for the treatment of pulmonary arterial hypertension (PAH), was evaluated for its potential as a perpetrator or victim of a metabolic and transporter\u2010based drug\u2010drug interactions in 2 phase 1 studies. In study 1, 24 participants received a cocktail of probe substrates: caffeine (CYP1A2), montelukast (CYP2C8), flurbiprofen (CYP2C9), midazolam (CYP3A), and pravastatin (OATP1B1\/1B3), plus digoxin (P\u2010gp) with or without seralutinib. In study 2, 19 participants received seralutinib with\/without itraconazole, a strong CYP3A inhibitor, or fosaprepitant, a weak CYP3A inhibitor. Geometric least\u2010squares mean ratios and 90% confidence intervals for maximum observed concentration (C<jats:sub>max<\/jats:sub>) and area under the plasma concentration\u2010time curve (AUC) were obtained. Safety was monitored throughout the studies. All adverse events were mild or moderate in severity. Seralutinib coadministration increased AUC for midazolam 3.03\u2010fold and caffeine 1.32\u2010fold. The coadministration increased digoxin C<jats:sub>max<\/jats:sub> 1.28\u2010fold. Seralutinib did not meaningfully alter C<jats:sub>max<\/jats:sub> and AUC for montelukast, flurbiprofen, or pravastatin. Fosaprepitant and itraconazole increased seralutinib AUC 1.08\u2010 and 1.84\u2010fold, respectively. Seralutinib is a moderate CYP3A inhibitor and a weak CYP1A2 inhibitor; it slightly inhibits P\u2010gp. Seralutinib exposure is minimally affected by a weak CYP3A inhibitor but is substantially increased by a strong CYP3A inhibitor.<\/jats:p>","DOI":"10.1002\/cpdd.1491","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T07:24:15Z","timestamp":1734938655000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug\u2010Drug Interactions in Healthy Participants"],"prefix":"10.1002","volume":"14","author":[{"given":"Jianke","family":"Li","sequence":"first","affiliation":[{"name":"Gossamer Bio, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Parsley","sequence":"additional","affiliation":[{"name":"Gossamer Bio, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Cravets","sequence":"additional","affiliation":[{"name":"Gossamer Bio, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"DeNoia","sequence":"additional","affiliation":[{"name":"ICON Early Phase Service  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Key","sequence":"additional","affiliation":[{"name":"ICON Early Phase Service  San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Mathias","sequence":"additional","affiliation":[{"name":"Gossamer Bio, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"issue":"3","key":"e_1_2_8_2_1","first-page":"S35","article-title":"Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients","volume":"27","author":"Levine DJ","year":"2021","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5539\/gjhs.v7n4p307"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-97"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106099"},{"issue":"3","key":"e_1_2_8_6_1","first-page":"S42","article-title":"The evolving treatment landscape of pulmonary arterial hypertension","volume":"27","author":"Gale S","year":"2021","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202012-4317SO"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040291"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024969"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02356-2021"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612653"},{"key":"e_1_2_8_12_1","article-title":"Phase 1a randomized, double\u2010blind, placebo\u2010controlled, single\u2010ascending dose and multiple\u2010ascending dose studies of orally inhaled GB002 in healthy adult subjects","volume":"201","author":"Li J","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211057071"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00072-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/20458940211046156"},{"issue":"4","key":"e_1_2_8_16_1","first-page":"51","article-title":"Phase 1 studies to assess inhaled seralutinib as a perpetrator or a victim of drug\u2010drug interactions in healthy subjects","volume":"12","author":"Li J","year":"2022","journal-title":"Pulm Circ"},{"issue":"6","key":"e_1_2_8_17_1","first-page":"789","article-title":"Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat","volume":"60","author":"Kot M","year":"2008","journal-title":"Pharmacol Rep"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200211209050667"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04086.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.039065"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037689"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.06.005"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02781.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.247"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12231"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09118-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)22834-8"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)22836-1"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.200"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1261"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.163"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.06.028"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010099"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.351"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.77"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.723"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250802017715"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250902846252"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011436344"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050542"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2020.103400"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300212s"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90114-4"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14157"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.83"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002766"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3329"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2014.01.001"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90001-6"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15699"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0222-8"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.626087"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2019.11.005"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010387792"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.562"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.06.042"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.11.023"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12668"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70009-3"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T10:26:06Z","timestamp":1738578366000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/cpdd.1491"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1491","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2024,12,22]]},"assertion":[{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}